Ernexa Therapeutics appoints former Schering-Plough CMO Robert J. Spiegel to board

By Public Technologies
  • Ernexa Therapeutics appointed Robert J. Spiegel to its board of directors.
  • Spiegel previously served as chief medical officer at Schering-Plough Research Institute from 1998 to 2009.
  • He later held a chief medical officer role at PTC Therapeutics from 2014 to 2016.
  • Spiegel is founder and principal of Spiegel Consulting LLC, also an associate professor at Weill Cornell Medical College.
  • Appointment comes as the company advances ERNA-101 toward clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170842PRIMZONEFULLFEED9828496) on September 17, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk